NowRx Inc. INVESTOR NOTICE: Squitieri Fearon LLP and Moore Law PLLC Announce that NowRx, Inc. Investors Have Opportunity to Lead Securities Class Action Lawsuit

Core Viewpoint - NowRx, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors about its financial condition and potential bankruptcy risks during the class period from February 1, 2022, to November 5, 2022 [1][5]. Company Overview - NowRx, Inc. is a private Delaware corporation founded in 2016, based in Mountain View, California, and operates as a tech-powered pharmacy offering same-day prescription delivery and telehealth services [2]. Financial Events - On September 30, 2021, NowRx initiated an offering under SEC Regulation A, proposing to sell up to 7,002,801 shares of Series C Preferred Stock at $10.50 per share [3]. - On November 30, 2022, NowRx announced an agreement to acquire Alto Pharmacy, which would take over prescription delivery and services for NowRx patients, leading to significant losses for Series C stock investors [4]. Allegations in the Lawsuit - The lawsuit alleges that NowRx and its executives failed to disclose critical information regarding the company's financial health, including: - The company was nearing bankruptcy or insolvency [5]. - An investment bank had been hired to explore a sale or raise funds for continued operations [5]. - As of December 31, 2021, NowRx was valued at $3.55 per share, significantly lower than the $10.50 per share offered to investors [5]. Legal Process - Investors who purchased NowRx securities during the class period can seek to be appointed as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [6]. - The deadline for filing lead plaintiff motions is January 23, 2026, as per the Private Securities Litigation Reform Act of 1995 [7].